8-K current report · filed Nov 5, 2026

Disc Medicine, Inc. (IRON) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1IRON overview

Short answer

Disc Medicine, Inc. (IRON) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results cover the quarter ended September 30, 2026.

Disc Medicine, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 results cover the quarter ended September 30, 2026
  • Corporate update announced alongside the quarterly financial results
  • Detailed financial figures and business developments available in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • APOLLO Phase 3 met all primary and secondary endpoints, materially strengthening bitopertin’s path toward EPP approval
  • Bitopertin reduced PPIX 41.4% versus placebo and increased monthly pain-free sunlight exposure by 12.2 hours
  • NDA resubmission planned by end-2026, with potential FDA decision anticipated by mid-2027
  • Cash $682.8M at Q3-end, plus $485.9M October offering proceeds, extending expected funding runway into 2030
  • Q3 net loss $59.5M, with R&D $44.1M and SG&A $20.1M; pipeline spending remains substantial despite lower quarterly loss

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Disc Medicine, Inc. 8-K filings

Get the next IRON 8-K as it lands

Follow IRON for push alerts, or ask the research agent what this filing means.